Avoid Errors With the New HIV Med, Dovato

July 2019

Dovato (doh-VAH-toh) will be a new complete HIV regimen with TWO meds in one pill...for treatment-naive patients.

It combines the integrase inhibitor dolutegravir with the nucleoside reverse transcriptase inhibitor lamivudine.

Dovato will try to compete with THREE-med, one-pill combos, such as Biktarvy (bictegravir/emtricitabine/tenofovir).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

MRSA Don't Switch From Vancomycin for MRSA Bacteremia Just for an MIC of 2 mg/L
Allergic Reactions Sort Through Options When Treating Patients Reporting a Penicillin Allergy
Liver Disease Maximize Safety When Using Anticoagulants in Patients With Cirrhosis
Asthma Don't Assume Using Combo Steroid Asthma Inhalers AS NEEDED Is Wrong
Infectious Diseases Don't Screen for UTIs in Most Patients Without Symptoms
Public Health Recognize Human Trafficking Victims Hidden in Plain Sight
HIV & AIDS Avoid Errors With the New HIV Med, Dovato
Drug Costs Be Prepared for Questions About Medication Prices in TV Ads
Devices Put Sensors for Inhalers in Perspective